Completed PHASE4 INTERVENTIONAL 2-arm NCT01059266

PURETHAL Grasses Rush Study

A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis

Sponsor: HAL Allergy

Conditions Allergic Rhinitis Allergic Rhinoconjunctivitis

Interventions PURETHAL Grasses, 20.000 AUM/ml

Updated 5 times since 2017 Last updated: Feb 9, 2012 Started: Feb 28, 2010 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01059266, this PHASE4 trial focuses on Allergic Rhinitis and Allergic Rhinoconjunctivitis and remains completed. Sponsored by HAL Allergy, it has been updated 5 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HAL Allergy

Data source: HAL Allergy

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bonn, Germany , Dortmund, Germany , Dresden, Germany , Duisburg, Germany , Frankfurt, Germany , Herford, Germany , Koblenz, Germany , Mahlow, Germany , Mönchengladbach, Germany , Stuttgart, Germany and 1 more location